Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Replay Bio

Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
From Replay Bio
Via GlobeNewswire
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
From Replay Bio
Via GlobeNewswire
Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy®
From Replay Bio
Via GlobeNewswire
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens
From Replay Bio
Via GlobeNewswire
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
From Replay Bio
Via GlobeNewswire
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma
From Replay Bio
Via GlobeNewswire
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
From Replay Bio
Via GlobeNewswire
Cristian Massacesi, M.D., Appointed to Replay Board of Directors
From Replay Bio
Via GlobeNewswire
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
From Replay Bio
Via GlobeNewswire
KKR-backed Replay and MD Anderson form new product company Syena to pioneer first-in-class TCR-NK cell therapy
From Replay Bio
Via GlobeNewswire
Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilising big DNA HSV technology
From Replay Bio
Via GlobeNewswire
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
From Replay Bio
Via GlobeNewswire
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
From Replay Bio
Via GlobeNewswire
Replay launches its first HSV gene therapy company, Eudora, focused on retinal eye disease
From Replay Bio
Via GlobeNewswire
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts
From Replay Bio
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.